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NON-INVASIVE IN VIVO MEASUREMENT OF	 jugated carbon backbone with alternating carbon-carbon
MACULAR CAROTENOIDS	 double (C	 C) and single (C—C) bonds and strong elec-
tronic absorptions. Studies by these researchers reportedly
RELATED APPLICATION 	 used resonance Raman spectroscopy for the measurement of
5 macular carotenoid levels in excised human eyecups from
	
This application claims the benefit of priority to U.S. Pro- 	 cadavers (Optics Letters 27, 10, 833-835 (2002)) and in living
	
visional Patent Application Ser. No. 60/445,046, entitled	 humans (J. Opt. Soc. Am. A.19, 6,1172-1186 (2002)). These
	
"Non-Invasive Measurement of Macular Carotenoids", filed	 studies reported a decline in the Raman signal correlated with
	
Feb. 5, 2003, the contents of which are hereby incorporated 	 increasing age. Id at 1183.
by reference as if recited in full herein. 	 10	 Despite the foregoing, there is a need for improved sys-
	
The invention described herein was made by an agency of 	 tems, methods, and devices for the non-invasive in vivo analy-
	
the United States Government or under a contract with an	 sis of carotenoids in the eye.
agency of the United States Government, namely in the per-
	
formance of work awarded by NASA under contract number	 SUMMARY OF THE INVENTION
NAS7-1407, and is subject to the provisions of Public Law 15
	96-517 (35 USC § 202) in which the Contractor has elected to 	 According to embodiments of the present invention, a non-
	
retain title. The United States Government has certain rights 	 invasive in vivo method for assessing carotenoids and/or ret-
to this invention.	 inoids in the macula and/or retina is provided. Optical Coher-
ence Tomography (OCT) can be performed on a retina of a
FIELD OF THE INVENTION	 20 subject. A spatial representation of carotenoid levels in the
retina based on data from the OCT of the retina can be gen-
	
The present invention concerns methods and apparatus for 	 erated.
	
non-invasively measuring or assessing the presence or 	 In some embodiments, OCT can be performed by trans-
absence of selected substances in the eye. 	 mitting a blue excitation light to the retina. In other embodi-
25 ments, an excitation light is transmitted that includes at least
BACKGROUND OF THE INVENTION	 a blue excitation light and an infrared excitation light. The
blue and/or infrared light can be a low coherence light trans-
	
Age related Macular Degeneration (AMD) is thought to be	 mitted with a superluminescent diode. In particular embodi-
	
the leading cause of blindness in the elderly. It has been 	 ments, a wavelet transformation can be applied to the OCT
estimated that about 12 million people in the United States 30 signal to generate spectral data of the retina. An absorption
	
suffer from AMD. Macular carotenoid pigments, such as 	 and/or reflectance spectrum of the retina can be obtained from
	
lutein and zeaxanthin, may play a role in the progression 	 the OCT, and carotenoid absorption levels can be identified
	
and/or onset of AMD. Carotenoids are from a family of natu- 	 therein.
	
ral pigments that are found in both plants and animals. Ani- 	 In some embodiments, the performing and generating
mals generally derive carotenoids from dietary sources such 35 steps can be repeated after the administration of a selected
	
as green leafy vegetables and orange and yellow fruits and 	 treatment to a subject to provide first and second spatial
	
vegetables. Epidemiological studies have shown that there is	 representations of the carotenoids of the retina. The treatment
	
an inverse correlation between high dietary intakes of caro- 	 or different types of treatment can be evaluated based on the
	
tenoids and blood levels of lutein and zeaxanthin and the risk 	 change of carotenoid levels in the retina. The first spatial
of advance AMD. See Eye Disease Case Control Study 40 representation can be compared with the second spatial rep-
	
Group, `Antioxidant status and neovascular age-related 	 resentation and the efficacy of the selected treatment for
	
macular degeneration," Arch. Ophthalmol (Chicago) 111,	 AMD can be evaluated based on the comparison.
	
104-109 (1993); J. M. Seddon, U. A. Ajani, R. D. Sperduto, R. 	 For example, carotenoids can include, but are not limited
	
Hiller, N. Blair, T. C. Burton, M. D. Farber, E. S. Gragoudas, 	 to, (3-carotene, lutein, lycopene, xanthophyl, xanthophyll,
J. Haller, D. T. Miller, L. A.Yannuzzi, and W. Willer, "Dietary 45 and zeaxanthin. The carotenoids can have a chemical struc-
	
carotenoids, vitamins A, C, and E, and advanced age-related 	 ture having at least one double carbon-carbon bonds and/or a
	
macular degeneration," 7.Am. Med. Assoc. 272, 1413-1420 	 single carbon-carbon bond. A detected light spectrum from
(1994).	 the OCT can be compared to a priori reference spectra corre-
	
It has been hypothesized that carotenoids may protect 	 sponding to different concentrations of a plurality of different
against AMD because of their free-radical-scavenging prop- 50 concentrations of the carotenoids. In some embodiments, a
	
erties as antioxidants. The ocular tissue may be at high risk of 	 retinoid concentration in the retina can also be determined. In
	
oxidative damage because of high levels of light exposure. 	 other embodiments, a resonant Raman spectra can be
	
Carotenoids absorb light in the blue-green spectral range; 	 detected based on the OCT data. In other embodiments, a
	
therefore, carotenoids may act as filters that can attenuate	 relative increase or decrease can be determined using at least
photo-chemical damage and/or image degradation caused by 55 two OCT scans taken over a desired timeframe.
	
short-wavelength visible light reaching the retina. See W.	 The OCT scan can be performed by scanning the retina
	
Gellerman; I. V. Ennakov, M. R. Ennakova, R. W. McClave; 	 with low coherence light of an OCT scanner, detecting
	
D. Y. Zhao, and P. S. Bernstein, "In vivo resonant Raman	 reemitted light from the retina in response thereto, interfering
	
measurements of macular carotenoid pigments in the young 	 the detected light from the retina with a reference light beam
and the aging human retina," J. Opt. Soc. Am. A, 19, 6, 60 to provide an interference signal, and obtaining a light spec-
1172-1186 (2002).	 trum from the interference signal.
	
Raman spectroscopy has been used to obtain spectra 	 In some embodiments reflectance and/or absorption spec-
	
indicative of carotenoid pigments in the retina. See Id.; W. 	 tra of a plurality of different layers of the retina can be
	
Gellerman; I. V. Ennakov, R. W. McClave, P. S. Bernstein, 	 detected. The plurality of different layers can include at least
"Raman imaging of human macular pigments," Optics Let-  65 seven layers. A two-dimensional map, or, typically, a three-
	
ters, 27, 10, 833-835 (2002). Lutein and zeaxanthin and other	 dimensional morphology map of carotenoid level in a cross-
	
carotenoid pigments feature a Raman-active, 7t-electron con-	 sectional spatial representation of the retina can be generated
US 7,593,763 B2
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from the OCT, for example, using amplitude and spectral data
of absorption and/or reflectance spectra from the OCT.
The spatial representation can be a map of a plurality of
adjacent layers of the retina and covers a region that may be
between about 2-5 mm wide. The spatial representation can
be presented with at least about 1000 pixels. Intensity gradu-
ated and/or color indexed images of different levels of caro-
tenoids in the retina can be generated. Age-related macular
degeneration (AMD) can be assessed based on the two- or
three-dimensional spatial representation of the carotenoid
levels.
In some embodiments, a combination of resonant Raman
data and OCT data can be obtained to assess the carotenoid
levels in the retina. For example, a portion of the retina can be
illuminated with an optical excitation beam having a wave-
length selected to generate a resonant Raman spectrum of at
least one of the carotenoids. A resonant Raman spectrum
corresponding to the selected illuminated region of the eye
can be detected. Resonant Raman data can be combined with
OCT data to generate the more precise level of chemical
concentration for a spatial representation of carotenoid levels
in the retina. The retina can be illuminated with the optical
excitation beam and the OCT data can be generated substan-
tially simultaneously. An OCT signal can be detected and the
resonant Raman spectrum can be filtered from the OCT sig-
nal.
In some embodiments, a system for providing non-invasive
in vivo assessment of macular carotenoids includes an OCT
scanner configured to generate an OCT scan of the retina. The
OCT scan can include chemical spectra and/or physical struc-
tures data of the eye. A carotenoid mapping module is in
communication with the OCT scanner and is configured for
generating a spatial representation of carotenoid levels in the
retina based on data obtained from the OCT scanner. In some
embodiments, the OCT scanner can include a blue excitation
light source and/or an infrared light source. The carotenoid
mapping module can be configured to apply a wavelet trans-
formation to an OCT signal from the OCT scanner to generate
spectral data of the retina.
In some embodiments, the system can include a Raman
excitation source having a wavelength selected to generate a
resonant Raman spectrum of at least one of the carotenoids. A
Raman spectrometer can be configured to receive the reso-
nant Raman spectrum. The carotenoid mapping module can
be configured to combine resonant Raman spectrum with
OCT data from the OCT scanner to generate a spatial repre-
sentation of carotenoid levels in the retina.
In some embodiments, a minimally invasive in vivo
method for assessing carotenoids in tissue of interest is pro-
vided. An OCT is performed on selected tissue of interest in
and/or on a subject, and a spatial representation of carotenoid
levels in the selected tissue is generated based on data from
the OCT of the region. The tissue of interest can include
internal organs, such as the bladder or prostate.
In other embodiments, a non-invasive in vivo method for
assessing retinoids in theretina and/or macula is provided. An
Optical Coherence Tomography (OCT) is performed on a
retina of a subject. A spatial representation of retinoid levels
in the retina is generated based on data from the OCT of the
retina.
Numerous additional features may be incorporated into the
apparatus. The device may include a visual display screen for
presenting visual indicia to the user, which can be individu-
ally adjusted and focused to the particular visual acuity of the
subject (similar to vision screening focusing procedures). The
apparatus may include a visual display screen for visually
displaying the results of the test to the subject and/or clinician
4
(such as through the same aperture or adjacent active matrix
screen) as which the test is conducted. It may include a visual
fixation target or device, also visible through the test aperture,
which controls movement of the eye and simultaneously
5 insures that focusing of the OCT beam is properly directed
into the retina of the eye.
BRIEF DESCRIPTION OF THE DRAWINGS
10 FIG.1 is a schematic of an image of an eye with a selected
target OCT scan line 2-2. FIG. 2 is a schematic of a cross
sectional slice taken from the scan line 2-2 from the image of
FIG. 1.
FIG. 3 is a schematic diagram of a data processing system
15 according to embodiments of the present invention.
FIG. 4 is a schematic diagram of an OCT device for mea-
suring carotenoids in vivo according to embodiments of the
present invention.
FIG. 5A-5B are a schematic diagrams of combination
20 OCT/Raman spectrometer devices for measuring carotenoids
in vivo according to embodiments of the present invention.
FIG. 6 is a schematic diagram of an OCT device for mea-
suring carotenoids in vivo according to embodiments of the
25 
present invention.
FIGS. 7 and 8 are flowcharts illustrating operations accord-
ing to embodiments of the present invention.
DESCRIPTION OF EMBODIMENTS OF THE
30	 INVENTION
The present invention will now be described more fully
hereinafter with reference to the accompanying figures, in
which embodiments of the invention are shown. This inven-
35 tion may, however, be embodied in many different forms and
should not be construed as limited to the embodiments set
forth herein. Like numbers refer to like elements throughout.
In the figures, layers, components, or features may be exag-
gerated for clarity and broken lines indicate optional features
40 or operations unless described otherwise.
The term "subject," according to the present invention,
includes subjects belonging to the animal kingdom, and are
preferably mammalian subjects (e.g., humans, canines,
felines, bovines, caprines, ovines, equines, rodents, porcines,
45 and/orlagomorphs), and more preferably are human subjects.
In some embodiments according to the invention, at least
one Optical Coherence Tomography (OCT) scan can be used
to provide a spatial representation of carotenoid and/or retin-
oid levels that may be present in the macula or other portions
50 of the retina. Although embodiments of the present invention
are described herein with reference to carotenoid levels, it
should be understood that some embodiments of the present
invention may be used to provide a spatial representation of
retinoid levels. In addition, although discussed primarily with
55 respect to OCT mapping of the retina, carotenoids or other
target regions/tissues inthe body can be assessed according to
embodiments of the present invention.
FIG. 1 is a schematic illustrating a typical fundus angio-
gram of a subject. FIG. 2 is a cross sectional schematic of an
60 image taken along line 2-2 in FIG. 1. As illustrated, areas of
low reflectivity are represented by a higher concentration of
markings. However, OCT scans typically use color or grey
scale drawings to represent the level of reflectivity/absorp-
tion. Images of fundus angiograms and OCT images are
65 described in "Optical Coherence Tomography of Ocular Dis-
eases" by Carmen A. Puliafito, Michael R. Hee, Joel S. Schu-
man, James G. Fujimoto (Slack, Inc. 1996). AMD can cause
US 7,593,763 B2
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blood vessels in the eye to leak, which can be observed
clinically using a fundus fluorescein angiogram. This leakage
can lead to blindness.
OCT techniques have been used to provide noninvasive,
cross-sectional optical imaging in biological media. Conven-
tional OCT devices may use a low coherent light source (e.g.,
a low coherent infrared diode) and an optical interferometer,
such as a Michelson optical fiber interferometer, to image
tissue as is known to those of skill in the art. Various OCT
techniques are described, for example, in U.S. Pat. No. 6,002,
480 to Izatt et al. and U.S. Pat. No. 6,608,684 to Gelikonov et
al., the disclosures of which are incorporated herein by ref-
erence in their entireties. These OCT techniques can generate
images, such as the image shown in FIG. 2, such that areas of
high reflectivity are represented by lighter shades than areas
of low reflectivity. Color images can also be generated such
that various levels of reflectivity are assigned to certain col-
ors.
According to embodiments of the present invention, an
excitation light can be transmitted to the macular pigment in
an OCT scan to generate absorption and/or reflectance spec-
tra. The absorption and/or reflectance can be used to identify
the presence and/or intensity of absorption and/or reflectance
spectra associated with carotenoids, such as (3-carotene,
lutein, lycopene, xanthophyl, xanthophyll, and/or zeaxan-
thin, and to generate a spatial representation of the identified
carotenoid levels. A blue excitation light may be used to
generate absorption and/or reflectance spectra and/or imag-
ing information. It should be understood that the absorption
spectrum may be measured indirectly. For example, a reflec-
tance spectrum can be used to generate an absorption spec-
trum. The blue light spectra wavelengths may coincide with
the absorption spectra of carotenoids. A blue excitation wave-
length can also be used in addition to a red or infrared exci-
tation light. As used herein, "infrared" includes near-infrared
light. In some embodiments, an OCT scan can be combined
with a Raman spectrum. A spatial representation of caro-
tenoid levels can be generated by combining the detected
Raman spectrum and OCT data, for example, by "overlaying"
a detected Raman spectrum on an OCT image. Examples of
Raman spectroscopy devices can be found, for example, in
U.S. Pat. No. 6,574,501, the disclosure of which is hereby
incorporated by reference in its entirety.
FIG. 3 is a block diagram of exemplary embodiments of
data processing systems that illustrates systems, methods,
and computer program products in accordance with embodi-
ments of the present invention. A data processing system 5
includes a processor 10 that can send and receive information
to and/or from an OCT scanner 25 and, optionally, in certain
embodiments, a Raman scattering system 20. The data pro-
cessing system 5, Raman scattering system 20 (where used)
and/or the OCT scanner 25 may be implemented noninva-
sively to scan the retina of a subject. It should be understood
that the OCT scanner 25 and/orthe optional Raman scattering
system 20 and/or the data processing system 5 may also be
used to perform OCT and (optionally) Raman scattering of
other biological tissues, including the prostate and/or the
bladder. The data processing system 5, the Raman scattering
system 20 and/or the OCT scanner 25 can be provided as
separate components or two or more systems or system com-
ponents can be provided as an integrated system.
As illustrated, the processor 10 communicates with the
memory 14 via an address/data bus 48. The processor 10 can
be any commercially available or custom microprocessor.
The memory 14 is representative of the overall hierarchy of
memory devices containing the software and data used to
implement the functionality of the data processing system 5.
6
The memory 14 can include, but is not limited to, the follow-
ing types of devices: cache, ROM, PROM, EPROM,
EEPROM, flash memory, SRAM, and DRAM. The memory
14 may include several categories of software and data used in
5 the data processing system 5: an operating system 52; appli-
cation programs 54; input/output (I/O) device drivers 58; and
data 56.
As will be appreciated by those of skill in the art, the
10 operating system 52 may be any operating system suitable for
use with a data processing system, such as OS/2, AIX,
OS/390 or System390 from International Business Machines
Corporation, Armonk, N.Y., Windows CE, Windows NT,
Windows95, Windows98, Windows2000 or WindowsXP
15 from Microsoft Corporation, Redmond, Wash., Unix or
Linux or FreeBSD, Palm OS from Palm, Inc., Mac OS from
Apple Computer, or proprietary operating systems. The I/O
device drivers 58 typically include software routines accessed
through the operating system 52 by the application programs
20 54 to communicate with devices such as I/O data port(s), data
56 and certain components of memory 14 components and,
optionally, where used, the Raman scattering system 20 or the
OCT scanner 25. The application programs 54 are illustrative
of the programs that implement the various features of the
25 data processing system 5 and preferably include at least one
application which supports operations according to embodi-
ments of the present invention. The data 56 represents the
static and dynamic data used by the application programs 54,
the operating system 52, the I/O device drivers 58, and other
3o software programs that may reside in the memory 14. The
data 56 may include OCT spectra data 56A, such as spectra
obtained from the OCT scanner 25 and, optionally, a record of
Raman spectra data 56B generated by the Raman scattering
35 
system 20.
As shown in FIG. 3, the application programs 54 can
include an OCT control module 62, a carotenoid mapping
module 66, and, optionally, Raman spectrometer control
module 64. The OCT control module 62 can control the
40 operation of the OCT scanner 25. Data from the OCT scanner25 can be stored as OCT spectra 56A in the data 56. The
optional Raman spectrometer control module 64 can control
the operation of the Raman scattering system 20, and data
from the Raman scattering system 20 can be stored in the
45 Raman spectra 56B. The carotenoid mapping module 66 can
generate a spatial representation of carotenoid levels that may
be present in the macula based on the OCT data of the macula,
and, in certain particular embodiments, based on both the
OCT data and the resonant Raman data.
50 For example, OCT spectra obtained from the OCT scanner
25 and stored in OCT spectra data 56A can be used by the
carotenoid mapping module 66 to represent a spatial distri-
bution of carotenoid levels in the macula using detected
absorption and/or reflectance spectra. The carotenoid map-
55 ping module 66 can apply a Morlet wavelet transformation to
an OCT signal to generate spectral data of the macula or other
portions of the retina. Phase information can also be obtained.
The carotenoid mapping module 66 can also use intensity
levels of the OCT signal, for example, to obtain structural
60 information.
Examples of the Morlet wavelet transformation are dis-
cussed in U. Morger, W. Drexler, F. X. Kartner, X. D. Li, C.
Pitris, E. P. Ippen, and J. G. Fujimoto, "Spectroscopic Optical
Coherence Tomography," 25, 2, Optics Letters, 111-113
65 (1999), the disclosure of which is hereby incorporated by
reference in its entirety. The Morlet wavelet transformation
can be mathematically expressed as follows:
US 7,593,763 B2
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W(SZ, r) _ if[„(t+r)exp[—(t/to)'lexp(iSZt)dt1 	 Equation (1)
= IF{[D(t+r)exp[(—t /to)2]}12
The above equation can be used to calculate an entire spec-
trum W(Q) for each point (x,i) in an OCT image, where x is
the distance in the transverse direction, to is an initial time, t is
a subsequent time, F is a Fourier transform, ID is the oscillat-
ing output from interference of the signal field with a Dop-
pler-shifted reference field from an OCT image scan, and "ti”
corresponds to detected light that is reemitted from a corre-
sponding depth z inside the tissue (i.e., such that light from
the reference path with a length z= T scanned continuously at
a speed g is interfered with light from the sample). Examples
of configurations that can be used to obtain an OCT scan,
including the detection of reemitted light from a sample and
a reference path, are discussed further below.
Other transformations to obtain spectral data can also be
used, such as Fourier transforms and/or other wavelet trans-
formations. Other computational methods can also be used to
characterize the absorption/reflectance spectra to obtain caro-
tenoid levels. For example, ratios of wavelengths in a spec-
trum can be examined to determine carotenoid levels.
Chemometric and/or ratiometric techniques, including
pulsed oximetry techniques, can also be used, such as pulsed
oximetry techniques described in U.S. Pat. No. 5,351,685, the
disclosure of which is hereby incorporated by reference in its
entirety. Chemometric techniques are described in "Chemo-
metric Techniques for Quantitative Analysis" by Richard
Kramer (Marcel Dekker, 1998). In some embodiments, a
portion of the peripheral retina, e.g., outside the macula, can
be scanned as a reference baseline for comparison with macu-
lar carotenoid levels. Carotenoid levels are generally higher
inside the macula or fovea.
In some embodiments, an entire spectrum can be calcu-
lated for each point in the OCT image. In certain embodi-
ments, the OCT scanner 25 can use a blue superluminescent
diode to generate the excitation light signal to the eye.
Ultrashort (femtosecond) pulsed light sources may also be
used. Without wishing to be bound by any particular theory,
carotenoids generally absorb blue light. Therefore, a blue
excitation light may increase sensitivity to the absorption
and/or reflectance spectra for carotenoids. Although blue
light may produce optimum ab sorption of retinal carotenoids,
it may also have lower penetration into the retina compared to
infrared light. Depending on the concentration and/or depth at
which the carotenoids are likely to be found, somewhat longer
wavelength excitation light may be utilized. In other embodi-
ments, the OCT scanner 25 can use a combination of light
bands, such as a blue light band and an infrared light band.
The blue light can be a low coherence light having a wave-
lengthrange between about 450 mu and about 550 mu and the
infrared light can include near infrared light and be a low
coherence light source having a wavelength range between
about 700 and about 1000 mu. The low coherence light of the
OCT scanner 25 can be spatially coherent and spectrally
incoherent. In some embodiments, a pulsed (femtosecond)
laser light source can be used.
As another example, the carotenoid mapping module 62
can combine OCT spectra data 56A and Raman spectra data
56B to provide a spatial representation of carotenoid levels.
The OCT spectra data 56A can be used to generate a mor-
phology or image of the macula or other parts of the retina
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with associated carotenoid (and/or retinoid) levels, and the
Raman spectra data 56B can provide spectra that can be used
to identify the presence and/or concentration of carotenoids
in a region of the macula or other parts of the retina. The
5 Raman spectra data 56B can be obtained using an excitation
beam selected to generate a resonant Raman spectrum for at
least one of the carotenoids in the retina. The Raman excita-
tion beam can be a high coherence light. The excitation wave-
length can be chosen to induce resonant or pre-resonant
10 Raman scattering of the macular carotenoids using a wave-
length between about 400 and 530 mu. As used herein, "reso-
nant' scattering includes "pre-resonant' or "strongly pre-
resonant' Raman scattering. Signal enhancements may allow
the observation of concentrations of macular carotenoids in
15 the nanogram of carotenoid per milligram of retina at these
wavelengths. However, significant absorption at these wave-
lengths may reduce the ability to examine carotenoids in
deeper layers of the retina. Excitation wavelengths of longer
wavelengths between 530 nm and 600 nm can be utilized to
20 induce pre-resonant Raman scattering of the macular caro-
tenoids. This can produce a signal enhancement of at least 10
or 1000 times over Raman scattering of macular carotenoids
using non-resonant excitation wavelengths while providing
deeper penetration into the macula or other parts of the retina.
25 In some embodiments, several millimeters of retinal layers
may be observed.
The OCT spectra data 56A can be obtained by the OCT
scanner 25 using a low coherence excitation light while the
Raman spectra data 56B can be obtained using a high coher-
30 ence excitation light, such as a laser; however, Raman spectra
may also be generated using a low coherence light. In some
embodiments, the Raman spectra can be generated using the
OCT light source, such as a low coherence blue or infrared
diode.
35 The system 5 can be used to generate a spatial representa-
tion of carotenoid levels present in the retina of a subject. In
certain embodiments, the actual signal of the subject can then
be compared to the stored "signature" profiles or signals of
OCT data and/or Raman data corresponding to predeter-
40 mined carotenoids or carotenoid levels to identify the pres-
ence of one or a plurality of the selected carotenoids and/or to
estimate or quantitatively determine the concentration of that
substance(s) in the retina of the eye of the subject. Thus, the
present invention is able to assess, non-invasively, at physi-
45 ologic levels, the presence of carotenoids in the retina of the
subject and to generate a spatial representation of the caro-
tenoid levels in two- or three-dimensions. For example, caro-
tenoids are conjugated polyenes and can have a chemical
structure having at least one, and more typically, a series of
5o alternating double carbon-carbon bonds and single carbon-
carbon bonds. The OCT spectra (or, optionally, the resonant
Raman spectra) may include peaks associated with the single
carbon-carbon bond or the double carbon-carbon bond of the
chemical structure. The OCT light spectra obtained from the
55 OCT scanner 25 can be compared to a priori reference spectra
corresponding to different concentrations of carotenoids.
In some embodiments, reflectance and/or absorption spec-
tra of different layers of the macula or other parts of the retina
can be collected, such as about three or four to about seven or
60 eight or more layers of cross sectional spatial representations
of carotenoid levels. A two-dimensional map or a three-di-
mensional map can be generated of carotenoid levels, for
example, using amplitude and spectral data of absorption
and/or reflectance spectra from the OCT scanner 25. For
65 example, a linear scan across the retina can consist, for
example, of 256 pixels across the retina and 100 pixels in
depth resolution, providing a 25600 pixel cross-sectional
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image. Typical pixel resolutions across the retina range from
50 to 1000 pixels. Depth resolution typically ranges from 10
to 250 pixels. The penetration depth of an OCT scan may be
about 3 mm for nontransparent tissues. The spatial represen-
tation of carotenoid levels can include intensity graduated 5
and/or color indexed images of different levels of carotenoids
in the retina.
The spatial representations of carotenoid levels canbe used
in assessing AMD. For example, epidemiological studies
and/or correlations between the spatial representations of io
carotenoid levels and AMD can be used to assess overall eye
health and/orAMD. The efficacy of various types of treatment
can also be assessed. Spatial representations of carotenoid
levels in the retina can be obtained before and/or after a
treatment is administered. Monitoring carotenoid levels 15
before and/or after treatment can assess whether a treatment
has affected the carotenoid levels. Treatments that may be
assessed in this manner include dietary changes, such as
carotenoids administered by vitamin supplements, eye drops,
or pharmacological agents or analytes, surgeries, exercise or 20
other interventional treatments. The systems and methods of
the present invention may also be used to evaluate, adjust
and/or identify therapies in drug/treatment development pro-
grams and/or in clinical or pre-clinical drug trials or other
drug development testing, including clinical or pre-clinical 25
trials for developing or evaluating vitamin supplements,
herbal remedies, and/or other treatments. Embodiments of
the present invention may also be used to evaluate, adjust
and/or identify a suitable dose of a selected treatment based
on the carotenoid levels in the eye.	 30
Although the present invention is illustrated in FIG. 3, for
example, with reference to the OCT control module 62, the
optional Raman spectrometer control module 64, and the
carotenoid mapping module 66 as examples of application
programs 54 in FIG. 3, as will be appreciated by those of skill 35
in the art, other configurations may also be utilized. For
example, the OCT control module 62, the optional Raman
scattering control module 64, and/or the carotenoid mapping
module 66 may also be incorporated into the operating sys-
tem 52, the I/O device drivers 58 or other such logical division 40
of the data processing system 5. Thus, the present invention
should not be construed as limited to the configuration of FIG.
3, which is intended to encompass any configuration capable
of carrying out the operations described herein.
The I/O device drivers 58 can be used to transfer informa- 45
tion between the data processing system 5 and the Raman
scattering system 20, the OCT scanner 25, or another com-
puter system or a local or global network (e.g., the Internet) or
to other devices controlled by the processor. These compo-
nents may be conventional components such as those used in 50
many conventional data processing systems that may be con-
figured in accordance with the present invention to operate as
described herein.
An exemplary OCT scanning system 100 is shown in FIG.
4. A light excitation source 114 provides an excitation light to 55
a beam splitter 116 via a fiber optic cable 118A. The beam
splitter 116 outputs a scanning excitation light beam on one
output fiber optic cable 122A and a reference beam on another
fiber optic cable 122B. The scanning and reference beams are
transmitted through lenses 124 and 126, respectively. The 60
scanning beam is transmitted to the macula 128M of the eye
128 and can be moved in a transverse direction to scan a cross
sectional area of the eye 128. The reference beam is transmit-
ted to a reference mirror 130, which can be moved away from
or toward the lens 126. The reemitted light from the reference 65
mirror 130 and the eye 128 are transmitted along fiber optic
cables 122A and 122B, respectively, through the beam split-
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ter 116 and to a detector 112. An OCT controller 110 analyzes
and interferes the resulting signals. The depth positions of the
reemitting locations in the eye 128 can be measured by chang-
ing the position of the reference mirror 130 with respect to the
lens 126. Thus, a cross sectional OCT scan can be measured
at various layers of depth within the eye 128.
As illustrated in FIG. 4, the light excitation source 114
includes a superluminescent blue light source 114A and,
optionally, an infrared light source 114B. The OCT scanning
system 100 can use the blue light source 114A and/or the
infrared light source 114B to provide a light excitation beam.
The blue light source 114A and/or the infrared light source
114B can be superluminescent diodes. Because carotenoids
generally absorb blue light, the blue light source 114A may be
used to provide an absorption and/or reflectance spectrum
that is sensitive in the blue range of the light spectrum and/or
imaging information. The infrared wavelengths may provide
increased depth penetration while the blue wavelengths may
provide increased sensitivity to the carotenoid levels. Alter-
natively, the infrared signal may be used to mask or reduce
any visual irritation that a subject may experience from a blue
excitation light alone. An interference signal from the infra-
red light source 114B may provide additional information for
imaging the carotenoid levels and/or an absorption and/or
reflectance spectrum.
The blue light source 114A and the infrared light source
114B can provide excitation beams in their respective wave-
lengthranges to the fiber optic cable 118A simultaneously. As
would be understood by those of skill in the art, if excitation
light beams are used from the blue light source 114A and the
infrared light source 114B at the same time, the detector 112
and/or the controller 110 can filter the resulting reemitted
light from the reference mirror 130 and the eye 128 to simul-
taneously analyze the interference spectrum associated with
the blue light source 114A and the infrared light source 114B.
Thus, two light spectra can be obtained from a single OCT
scan using the two light sources 114A, 114B. Alternatively,
the infrared source 114B can be used to mask the blue light
and the resulting spectra can be disregarded.
Alternatively, an OCT scan can be performed using only
the blue light source 114A and a separate OCT scan can be
performed using only the infrared light source 114B. As
another example, either the blue light source 114A or the
infrared light source 114B can be omitted from the OCT
scanning system 100.
The operations discussed with respect to the data process-
ing system 5 in FIG. 3 can be incorporated into the OCT
controller 110.
Referring to FIG. 5A, a combination OCT/Raman scatter-
ing system 200 includes an OCT light source 206 and a
Raman laser 204. The OCT light source 206 can include a
blue and/or infrared light source, such as a diode, as described
with respect to the embodiments of FIG. 4. Excitation beams
from the OCT light source 206 and/or the Raman laser 204
can be transmitted via fiber optic cables 224A and 224B,
respectively, to a beam splitter 230, which is connected to
another beam splitter 210 by fiber optic cable 234. The exci-
tation beam(s) can be transmitted via a fiber optic cable 214A
and a lens 216 to a macula 220M of an eye 220. The excitation
beam from the OCT light source 206 can also be transmitted
via a fiber optic cable 214B and a lens 218 to a reference
mirror 222 to provide a reference beam similar to the refer-
ence beam described with respect to FIG. 4. An OCT detector
202 and an OCT controller 212 is connected to another beam
splitter 232 by a fiber optic cable 226A, and a Raman spec-
trometer 228 is connected to the beam splitter 232 by a fiber
optic cable 226B. The beam splitter 232 is connected to the
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beam splitter 210 by a fiber optic cable 236. The OCT con-
troller 212 can analyze the interference spectra from the eye
220 and the reference mirror 222 at various depth levels as
described with respect to the controller 110 in FIG. 4.
As illustrated in FIG. 5A, excitation beams can be trans-
mitted to the eye 220 from the OCT light source 206 and the
Raman laser 204 simultaneously in a single scan or, alterna-
tively, in two separate scans: one scan for collecting OCT
spectra and one scan for collecting Raman spectra. In some
embodiments, the OCT light source 206 is an infrared diode
that can provide detailed imaging information of the eye 220.
The Raman spectra from the Raman spectrometer 228 can be
used to provide carotenoid concentrations in the same region
by identifying the characteristic Raman spectrum of caro-
tenoids from the collected Raman spectra from the eye 220.
The Raman spectra can be combined with imaging informa-
tion from the OCT scan, e.g., by "overlaying" the Raman
spectra with the OCT image.
In some embodiments, the OCT light source 206 is a blue
diode that can provide both imaging information and caro-
tenoid level information using the techniques described
herein, e.g., such as the techniques described with respect to
FIGS. 3 and 4. The Raman spectra can be combined with the
imaging and/or carotenoid levels from the OCT scan to pro-
vide enhanced carotenoid level information, such as informa-
tion at multiple depth layers in the macula 220M of the eye
220.
In some embodiments, a blue diode excitation beam, an
infrared diode excitation beam, a Raman laser excitation
beam or a combination thereof can be provided substantially
simultaneously. The resulting reemitted light from the macula
220M can be obtained and filtered and/or analyzed to provide
Raman spectra and/or OCT spectra information indicating
various carotenoid levels and/or OCT imaging information.
In other embodiments, a blue diode excitation beam, an infra-
red diode excitation beam, and/or a Raman laser excitation
beam can be used during separate OCT or Raman scans to
provide separate Raman and OCT information that can be
subsequently combined to provide the spatial representation
of carotenoid levels in the retina.
The Raman laser 204 can transmit an excitation beam
selected to generate a resonant Raman spectrum for at least
one of the carotenoids in the retina. For example, the Raman
laser 204 can transmit light at a wavelength between about
400 and 530 mu. In some embodiments, light sources, such as
• Raman laser and/or a blue low coherent light source, and/or
• Raman spectrometer can be added to a convention OCT
scanning device, which typically includes an infrared light
source. These components canbe added to conventional OCT
scanning devices as modular components on existing devices.
Conventional OCT scanning devices are commercially avail-
able from Carl Zeiss Meditec, Inc 5160 Hacienda Dr, Dublin,
Calif. (U.S.A.).
For example, as illustrated in FIG. 513, a conventional OCT
scanning device can include an infrared low coherent light
source 250, an infrared OCT detector 262, a reference lens
264, a reference mirror 266, scanning lenses 268, 272, and an
"X/Y" cross sectional scanner 270 that is configured to per-
form an OCT scan of an eye 274. The components that can be
added to the OCT scanning device include a blue light source
252 and bandpass filters 256, 258 connected to detectors 254,
260, respectively. The components of the OCT scanning
device shown are connected as illustrated in FIG. 5B by fiber
optic cables 276. The blue light source 252 can be a low
coherent light source, such as a blue superluminescent diode,
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or the blue light source 252 can be a blue laser. The blue light
source 252 can be configured to provide a Raman excitation
beam to the eye 274.
In some embodiments, the blue light source 252 can pro-
s duce resonant Raman scattered light from macular caro-
tenoids at 1008, 1159, and 1525 cm- ' wavenumbers. For
example, using a source excitation wavelength of 488 mu, a
1525 cm- ' carotenoid Raman peak can occur at 527.25 mu.
As illustrated in FIG. 513, this peak can be detected by detec-
io for 260 using the optical bandpass filter 258 (e.g., a bandpass
filter having a width of 2 mu). This peak can be compared to
scattered light at a wavelength where resonant Raman scat-
tering due to the presence of carotenoids is not expected, such
as at 521.1 mu (corresponding to a wavenumber of 1300
15 cm- '). This scattered light can be detected by detector 254
using the optical bandpass filter 256. The ratio of these two
values as a function of the position of the cross sectional
scanner 270 may be used to map carotenoid levels across the
retina. The blue light source 252 may be switched off, and the
20 infrared OCT light source 250, which can be supplied with a
conventional OCT scanner, may be used to provide an OCT
scan of the eye. Alternatively, the blue light source 252 and
the infrared light source 250 can be used substantially simul-
taneously. The carotenoid levels can be detected using spec-
25 tral information from the blue light source 252, including
resonant Raman spectra, and the carotenoid levels can be
mapped onto structural features of the retina revealed using
an infrared OCT scan with infrared light source 250.
Further embodiments of an OCT scanning system 300 are
30 shown in FIG. 6. As illustrated, the OCT scanning system 300
includes an OCT excitation light source 304 having a blue
light source 304A and/or an infrared light source 304B. An
excitation beam is transmitted from the light source 304
through a beam splitter 308 to a lens 310 that focuses the light
35 on a macula 312M of an eye 312. The beam splitter 308 also
transmits the excitation beam to a reference mirror 306. The
light that is reemitted from the reference mirror 306 and the
eye 312 is detected by a detector 302 and processed by an
OCT controller 314. The configuration shown in FIG. 6 is
40 generally referred to as a Michelson interferometry configu-
ration. The reference mirror 306 can be moved towards and
away from the beam splitter 308 to provide depth information
to the controller 314. The excitation beam through the lens
310 can be moved in a traverse direction to provide a cross-
45 sectional scan of the eye 312. The controller 314 can analyze
the resulting interference signal and the OCT absorption and/
or reflectance spectra to provide one or more cross sectional
spatial representations of carotenoid levels in the macula
312M of the eye 312.
50 Operations that can be performed by the systems described
herein are shown in FIG. 7. An OCT scan can be performed on
a retina of a subject at Block 400. The OCT scan can be used
to generate a spatial representation of carotenoid levels in the
retina at Block 402. For example, a wavelet transformation
55 and/or a Fourier transformation can be applied to the OCT
signal to obtain spectral data. The spectral data and the inten-
sity of the OCT signal can be used to generate structural and
spectral data for spatial points in the retina. A characteristic
absorption and/or reflectance spectra for carotenoids can be
60 identified. For example, the spectral data can be analyzed
using various mathematical techniques, including Fourier
transforms and wavelet transforms. As another example,
ratios of wavelengths can be examined to determine caro-
tenoid levels. Chemometrics and/or pulsed oximetry tech-
65 piques can also be used. The identified characteristic absorp-
tion and/or reflectance spectra can also be characteristic of the
concentration of carotenoids in the retina. The concentrations
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of carotenoids can then be mapped in a two- and/or and
three-dimensional morphology spatial representation of the
target regions of the eye.
Further operations that can be performed by the systems
described herein are shown in FIG. 8. An OCT image is 5
generated at Block 410. The retina is illuminated with a
Raman optical excitation beam having a wavelength selected
to generate a resonant Raman spectrum of at least one of the
carotenoids at Block 412. A resonant Raman spectrum cor-
responding to the retina is detected at Block 414. The detected io
Raman spectrum is combined with the OCT image of the
retina to generate a spatial representation of carotenoid levels
that may be present in the retina at Block 416.
Although embodiments of the present invention have been
described herein with reference to ocular OCT scans on the 15
retina or macula, it should be understood that the methods and
systems described herein may be applied to other areas of the
body. More particularly, minimally invasive in vivo methods
for assessing carotenoids in a tissue of interest can include
performing OCT on a selected tissue of interest of a subject. 20
The selected tissue can include the skin or internal organs,
such as the bladder and prostate. A spatial representation of
carotenoid levels in the selected tissue can be generated based
on data from the OCT of the region using the techniques
described herein. 	 25
For example, OCT scan of other tissue can be made using
non-invasive or minimally invasive techniques, including
techniques using probes, such as those described in U.S. Pat.
No. 6,564,087, the disclosure of which is hereby incorporated
by reference in its entirety. OCT scanning probes can be 30
inserted directly into a tissue or organ through a tissue wall
and/or into a natural lumen of a hollow organ or space (such
as into a sinus cavity, a blood vessel, or other body cavity).
Carotenoids in other areas of the body include carotenoids
that absorb blue, yellow, red, green or other wavelengths of 35
light. For example, lycopene is typically red in color. Appro-
priate OCT excitation light sources can be based on the caro-
tenoid of interest, the selection of which would be known to
those of skill in the art. For example, the OCT light source
used can be selected so that some of the excitation wave- 40
lengths are absorbed by carotenoids of interest.
OCT scans of organs, such as the bladder and prostate, can
be used to evaluate carotenoid levels therein. The overall
health of tissue and/or the efficacy of various types of treat-
ment can also be assessed. Spatial representations of caro- 45
tenoid levels in the tissue can be obtained before and/or after
a treatment is administered. Embodiments of the present
invention may also be used to evaluate, adjust and/or identify
a suitable dose of a selected treatment based on the carotenoid
levels.	 50
Additionally, as noted above, while embodiments of the
present invention are described herein with reference to caro-
tenoids, it should be understood that levels of other sub-
stances may also be detected. In particular, the techniques
described herein may also be used to generate a spatial rep- 55
resentation of retinoid levels in a selected tissue of a subject
based on data from an OCT scan of the tissue region. For
example, retinoids may also be detected using data from an
OCT scan of an area of the retina using an OCT light source
selected to provide an absorption and/or reflectance spectrum 60
an/or a Raman scattering spectrum. The wavelengths of the
excitation light source canbe selectedbased on the absorption
or Raman scattering characteristics of the retinoid of interest.
For example, the excitation light source can emit wavelengths
between about 400 and about 450 mu. Retinoid levels maybe 65
assessed, for example, in the treatment or assessment of ocu-
lar conditions, such as retinitis pigmentosa.
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The foregoing is illustrative of the present invention and is
not to be construed as limiting thereof. Although a few exem-
plary embodiments of this invention have been described,
those skilled in the art will readily appreciate that many
modifications are possible in the exemplary embodiments
without materially departing from the novel teachings and
advantages of this invention. Accordingly, all such modifica-
tions are intended to be included within the scope of this
invention as defined in the claims. Therefore, it is to be under-
stood that the foregoing is illustrative of the present invention
and is not to be construed as limited to the specific embodi-
ments disclosed, and that modifications to the disclosed
embodiments, as well as other embodiments, are intended to
be included within the scope of the appended claims. The
invention is defined by the following claims, with equivalents
of the claims to be included therein.
That which is claimed is:
1.A non-invasive in vivo method for assessing carotenoids
in the retina and/or macula, comprising:
performing Optical Coherence Tomography (OCT) on a
retina of a subject to obtain absorption and/or reflectance
spectral data correlated with carotenoid levels; and
generating a spatial representation of carotenoid levels in
the retina based on comparing the spectral data from the
OCT of the retina with a priori reference spectra.
2. A method according to claim 1, wherein the performing
step comprises transmitting a blue excitation light to the
retina.
3. A method according to claim 1, wherein the performing
step comprises transmitting an excitation light comprising a
blue excitation light and an infrared excitation light.
4. A method according to claim 1, wherein the generating
step comprises applying a wavelet transformation to an OCT
signal to generate spectral data of the retina.
5. A method according to claim 1, wherein the performing
step comprises transmitting a low coherence light with a
superluminescent diode.
6. A method according to claim 1, wherein the generating
step comprises repeating the performing and generating steps
after administration of a selected treatment to provide a first
and second spatial representation of carotenoid levels in the
retina.
7.A method according to claim 6, further comprising com-
paring the first spatial representation with the second spatial
representation and evaluating the efficacy of the selected
treatment on age related macular degeneration (AMD) based
on the comparing step.
8. A method according to claim 1, wherein the carotenoids
include at least one of (3-carotene, lutein, lycopene, xantho-
phyl, xanthophyll, and/or zeaxanthin.
9. A method according to claim 1, wherein carotenoids of
interest have a chemical structure having at least one alter-
nating double carbon-carbon bonds and/or single carbon-
carbon bonds.
10. A method according to claim 1, wherein the a priori
reference spectra corresponds to a plurality of different
known concentrations of the carotenoids.
11.A method according to claim 1, wherein the generating
step is able to determine a retinoid concentration level in the
retina.
12. A method according to claim 1, further comprising
detecting a resonant Raman spectra based on the OCT data.
13.A method according to claim 1, wherein the performing
step comprises:
scanning the retina with low coherence light of an OCT
scanner;
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detecting reemitted light from the retina in response
thereto;
interfering the detected light from the retina with a refer-
ence light beam to provide an interference signal; and
obtaining the spectral data from the interference signal. 	 5
14.A method according to claim 1, wherein the performing
step comprises detecting reflectance and/or absorption spec-
tra of different layers of the retina.
15. A method according to claim 14, wherein the different
layers includes at least seven layers. 	 10
16.A method according to claim 1, wherein the generating
step comprises generating a two-dimensional map of caro-
tenoid levels in a cross-sectional spatial representation of the
retina from the OCT.
17.A method according to claim 1, wherein the generating 15
step comprises generating a three-dimensional morphology
map of carotenoid levels in the retina.
18. A method according to claim 1, wherein the spatial
representation comprises a map of a plurality of adjacent
layers of the retina and covers a region about 2-5 mm wide. 20
19. A method according to claim 1, wherein the spatial
representation comprises at least about 1000 data pixels.
20.A method according to claim 1, wherein the generating
step comprises generating an intensity graduated and/or color
indexed image of different levels of carotenoids in the retina. 25
21. A method according to claim 1, further comprising
assessing age-related macular degeneration (AMD) based on
the spatial representation of the carotenoid levels.
22.A method according to claim 1, wherein the performing
step comprising performing OCT on the macular portion of 30
the retina.
16
23.A method according to claim 1, wherein the performing
step comprises transmitting a low coherence light to a portion
of the retina.
24. A non-invasive in vivo method for assessing caro-
tenoids in the retina and/or macula, comprising:
performing Optical Coherence Tomography (OCT) on a
retina of a subject to obtain spectral data correlated with
carotenoid levels; and
generating a spatial representation of carotenoid levels in
the retina based on comparing the spectral data from the
OCT of the retina with a priori reference spectra, the
method further comprising:
illuminating a portion of the retina with an optical excita-
tion beam having a wavelength selected to generate a
resonant Raman spectrum of at least one of the caro-
tenoid;
detecting a resonant Raman spectrum corresponding to the
selected illuminated region of the eye; and
combining resonant Raman spectrum data with OCT data
to generate the spatial representation of carotenoid lev-
els in the retina.
25. A method according to claim 24, wherein the generat-
ing and illuminating steps are performed substantially simul-
taneously.
26. A method according to claim 25, wherein the generat-
ing step further comprises filtering the resonant Raman spec-
trum from the OCT spectral data.
